Share This Page
Drugs in ATC Class D07A
✉ Email this page to a colleague
Subclasses in ATC: D07A - CORTICOSTEROIDS, PLAIN
D07A Market Analysis and Financial Projection
The ATC Class D07A - CORTICOSTEROIDS, PLAIN encompasses corticosteroid-based dermatological preparations categorized by potency, including drugs like methylprednisolone, hydrocortisone, and prednisolone. These are primarily used to treat inflammatory skin conditions such as eczema, psoriasis, and dermatitis. Below is an analysis of the market dynamics and patent landscape shaping this segment:
Market Dynamics
Growth Drivers
-
Rising Prevalence of Skin Disorders:
- The global corticosteroids market was valued at USD 5.3 billion in 2023, with a projected CAGR of 5.49% through 2030 [13]. The dominance of topical corticosteroids (part of D07A) is driven by increasing cases of eczema, dermatitis, and psoriasis, especially among aging populations. By 2050, 16% of the global population will be over 65, a cohort highly susceptible to skin conditions [8][18].
-
Technological Advancements:
- Innovations in formulations enhance efficacy while reducing side effects. For example, US Patent 8,809,307 [16][19] describes topical corticosteroids with reduced concentrations but maintained potency using dicarboxylic acid esters.
-
Strategic Collaborations:
- Companies like Eli Lilly are advancing R&D, such as combining lebrikizumab (an IL-13 inhibitor) with topical corticosteroids for atopic dermatitis, showing improved clinical outcomes [17].
Market Segmentation
- By Potency: Weak (Group I, e.g., hydrocortisone), moderately potent (Group II), potent (Group III), and very potent (Group IV, e.g., clobetasol) [15].
- By Region: North America dominates due to high healthcare spending, while Asia-Pacific grows rapidly with expanding access to dermatological care [8][10].
| Key Market Metrics | Value | Source |
|---|---|---|
| Global Market Size (2023) | USD 5.3 billion | [3][8] |
| Topical Corticosteroids CAGR | 6.1% (2023–2030) | [17] |
| Leading Application | Skin Allergies | [8] |
Patent Landscape
Historical Innovations
- Pfizer’s Process Patents: Early patents for producing prednisone and prednisolone (1957) laid the foundation for systemic and topical corticosteroids [4].
- Modern Formulations: Patent 8,809,307 (2014) by Dow Pharmaceutical Sciences optimizes topical delivery using ester-based vehicles, addressing potency retention at lower doses [16][19].
Strategic Trends
- Defensive Patenting: Companies like GSK and Novartis build portfolios to block competitors and secure freedom-to-operate [2].
- Collaborative R&D: Joint ventures (e.g., AI firms partnering with pharmaceutical giants) focus on novel delivery mechanisms and combination therapies [2][11].
- Open-Source Initiatives: Some companies share patents to accelerate innovation, such as non-aggression pacts in autonomous vehicle tech, a trend mirroring in dermatology [2].
Challenges
- Regulatory Hurdles: Stricter safety evaluations for high-potency corticosteroids delay approvals [18].
- Patent Expirations: Generic competition pressures revenue, exemplified by methylprednisolone (DB00959) and prednisolone (DB00860) entering public domains [6][9].
Future Outlook
- Biosimilars and Generics: Post-2030, biosimilar adoption will intensify, particularly in Europe and Asia [13].
- New Applications: Expansion into pediatric formulations and combo therapies (e.g., corticosteroids + biologics) [13].
- Digital Health Integration: Patents for IoT-enabled delivery systems (e.g., smart applicators) may emerge, following trends in digital health patent filings [11].
“The future of corticosteroid innovation lies in balancing efficacy with safety through advanced formulations and collaborative R&D.” – Adapted from industry trends [2][16].
Key Takeaways:
- Market Growth: Driven by aging demographics and chronic skin diseases.
- Innovation Focus: Enhanced delivery systems and strategic IP management.
- Competitive Risks: Patent cliffs and regulatory barriers require agile R&D strategies.
FAQs
- Which potency class dominates D07A?
Weak corticosteroids (Group I, e.g., hydrocortisone) due to widespread use in mild conditions [15]. - How does Pfizer’s legacy impact the market?
Early patents set precedents, but generics now dominate older molecules [4][6]. - What regions show the fastest growth?
Asia-Pacific, driven by healthcare infrastructure improvements [8][10]. - Are topical corticosteroids safe long-term?
Lower-potency formulations are preferred for chronic use to minimize side effects [14]. - What’s next for D07A patents?
Focus on nanotechnology and hybrid drugs to improve bioavailability [16][19].
Sources: [2][3][4][6][8][9][10][13][14][15][16][17][18][19]
References
- https://www.marketsandmarkets.com/Market-Reports/air-traffic-control-equipment-market-159216929.html
- https://patentpc.com/blog/understanding-the-patent-landscape-for-autonomous-vehicle-technologies
- https://www.grandviewresearch.com/industry-analysis/corticosteroids-market-report
- https://pubs.acs.org/doi/10.1021/cen-v035n004.p028a
- https://patents.google.com/patent/US20190017912A1/en
- https://go.drugbank.com/drugs/DB00959
- https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2018/belgian-reg-med-best-performers-for-october-2018.pdf?la=sk-sk&hash=5F03C3AA6255CA928A6446DA47F98DC6
- https://www.mordorintelligence.com/industry-reports/corticosteroids
- https://go.drugbank.com/drugs/DB00860
- https://www.gminsights.com/industry-analysis/corticosteroids-market
- https://www.i-jmr.org/2024/1/e48259
- https://www.fortunebusinessinsights.com/air-traffic-control-atc-market-102957
- https://www.thebusinessresearchcompany.com/report/corticosteroid-global-market-report
- https://atcddd.fhi.no/atc_ddd_index/?code=D07A
- https://en.wikipedia.org/wiki/ATC_code_D07
- https://www.drugpatentwatch.com/p/patent/8809307
- https://www.databridgemarketresearch.com/reports/global-topical-corticosteroids-market
- https://www.databridgemarketresearch.com/reports/north-america-topical-corticosteroids-market
- https://patents.google.com/patent/US8809307B2/en
More… ↓
